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OBJECTIVES To assess the clinical course of patients who have undergone coronary stent placement less
than six weeks before noncardiac surgery.
BACKGROUND Surgical and percutaneous transluminal coronary angioplasty revascularization performed
before high-risk noncardiac surgery is expected to reduce perioperative cardiac morbidity and
mortality. Perioperative and postoperative complications in patients who have undergone
coronary stenting before a noncardiac surgery have not been studied.
METHODS Forty patients who underwent coronary stent placement less than six weeks before noncardiac
surgery requiring a general anesthesia were included in the study (1–39 days, average: 13
days). The records were screened for the occurrence of adverse clinical events, including
myocardial infarction, stent thrombosis, peri- and postoperative bleeding and death.
RESULTS In 40 consecutive patients meeting the study criteria, there were seven myocardial infarctions
(MIs), 11 major bleeding episodes and eight deaths. All deaths and MIs, as well as 8/11
bleeding episodes, occurred in patients subjected to surgery fewer than 14 days from stenting.
Four patients expired after undergoing surgery one day after stenting. Based on electrocar-
diogram, enzymatic and angiographic evidence, stent thrombosis accounted for most of the
fatal events. The time between stenting and surgery appeared to be the main determinant of
outcome.
CONCLUSIONS Postponing elective noncardiac surgery for two to four weeks after coronary stenting should
permit completion of the mandatory antiplatelet regimen, thereby reducing the risk of stent
thrombosis and bleeding complications. (J Am Coll Cardiol 2000;35:1288–94) © 2000 by
the American College of Cardiology
Preoperative identification and treatment of coronary artery
disease (CAD) is a commonly accepted practice when
referring patients for noncardiac surgery requiring general
anesthesia. This practice is felt to reduce perioperative
morbidity and mortality (1). Studies indicate that patients
with CAD who are revascularized by coronary artery bypass
grafting (CABG) before undergoing noncardiac surgery
have a reduced incidence of myocardial infarction (MI) and
postoperative death (2). The impact of percutaneous trans-
luminal coronary angioplasty (PTCA) procedures on the
complications after noncardiac surgery is less explored.
Several clinical studies have examined perioperative compli-
cations in patients who underwent PTCA before noncardiac
surgery and found a low perioperative morbidity (3–6).
However, no studies to date have reviewed postoperative
outcomes in patients who undergo PTCA and implantation
of a coronary stent before a noncardiac surgery.
Therefore, this study attempted to estimate whether
similar perioperative benefit exists for patients who undergo
PTCA with stent placement before noncardiac surgery.
METHODS
Between 1996 and the end of 1998 at the Methodist
Hospital, Houston, Texas, 40 consecutive patients who
underwent coronary stent placement less than six weeks
before a noncardiac surgical procedure requiring general
anesthesia were identified. The records were reviewed and
surgical outcomes were carefully scrutinized for evidence of
adverse clinical events such as: stent thrombosis, MI,
bleeding complications and death in the perioperative pe-
riod. Special attention was given to initiation, withdrawal
and continuation of each patient’s antiplatelet therapy dur-
ing the perioperative and postoperative period.
Bleeding complications were more difficult to grade as
many of the surgical procedures performed are considered
inherently associated with high blood loss. Excessive bleed-
From the Methodist Hospital, Baylor College of Medicine, Houston, Texas. This
study was financed by the Cardiac Cath Lab Research Center, the Methodist Hospital
Research Foundation, Houston, Texas.
Manuscript received May 11, 1999; revised manuscript received September 20,
1999, accepted December 15, 1999.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00521-0
ing was, therefore, defined as the postoperative need for
transfusion or bleeding that necessitated reoperation. Un-
usual blood loss or drainage in the perioperative period was
also assessed. Myocardial infarction was diagnosed by char-
acteristic electrocardiogram (ECG) changes or an increase
in creatinine kinase levels.
Statistical analysis. Continuous variables are presented as
mean value 6 SD. Discrete variables are described as
frequencies and percentages and were compared by chi-
square and Fisher exact test. P , 0.05 was considered
statistically significant.
RESULTS
The 40 patients included in this study underwent surgery 1
to 39 days after coronary stent placement (average 13 days).
The surgical procedures included: carotid endarterectomy
(n 5 12), thoracic or abdominal aortic aneurysm resection
(n 5 9), aortoiliac bypass grafting (n 5 2), aortobifemoral of
femoral-popliteal bypass grafting (n 5 3), arteriovenous
shunt placement or revision (n 5 2), mitral valve replace-
ment (n 5 1), lung transplantation (n 5 1), cholecystec-
tomy (n 5 2), sigmoid colectomy (n 5 1), femoral embo-
lectomy (n 5 1), nephrectomy (n 5 1), prostatectomy (n 5
1), left upper lobectomy of the lung (n 5 1), foot amputa-
tion (n 5 1), parathyroidectomy (n 5 1) and cystectomy
(n 5 1).
All 40 patients received at least one dose of ticlopidine
(250–500 mg) immediately after the stenting procedure. All
patients were receiving aspirin before stenting. Both anti-
platelet drugs were continued after stenting for a variable
period of time. Nine patients received abciximab during
coronary intervention.
The CAD history, risk profile and procedural details of
the studied group are summarized in Table 1.
Eight out of 40 patients expired. Relevant clinical details
of the patients who expired are summarized in Table 2. In
six patients (A.S., G.W., H.L., W.A., V.G., J.C.), death
was related to MI. In two other patients (R.C., J.H.), death
was associated with a bleeding complication. Four patients
(G.W., H.L., W.A., J.C.) had both MI and bleeding
complications ultimately leading to death. Seven patients
suffered MIs, of which six were fatal and one (F.D.) was
minimized due to successful emergent PTCA. Of these
seven patients, two had single vessel disease, three had
double vessel disease and two had triple vessel disease. All
critically stenosed vessels were successfully stented. In three
patients (A.S., G.W., V.G.) the residual diseased vessels
had lesions of borderline severity (50%) and were not
associated with demonstrable ischemia. In two patients
(F.D., W.A.), the untreated vessels were right coronary
arteries (RCAs), which were chronically occluded and
well-collateralized.
Stent thrombosis was presumed to be the cause of all of
the MIs; in two patients (F.D., J.C.), stent thrombosis was
confirmed angiographically. In four others, ECG changes of
infarction or ischemia were in the areas subtended by the
stented artery. One patient (G.W.) who experienced chest
pain and sudden death at home had triple vessel disease with
two severe stenoses (left anterior descending coronary artery
[LAD] and RCA), which were treated with multiple stents.
All deaths and MIs as well as 8 of 11 bleeding episodes
occurred in patients who underwent surgery in less than two
weeks after coronary stent placement. The incidence of
death and MI was significantly higher in this subset than it
was in patients subjected to surgery more than 14 days after
stenting (p 5 0.015 by Fisher exact test). As such, the
mortality rate among 25 patients operated within this
two-week timeframe was 32%. Of five patients who under-
went surgery one day after stenting, four expired (bleeding
was involved in three patients). The fifth patient underwent
surgery the day after stent placement, had no discontinua-
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
CAD 5 coronary artery disease
CX 5 circumflex coronary artery
ECG 5 electrocardiogram
LAD 5 left anterior descending coronary artery
MI 5 myocardial infarction
OM 5 obtuse marginal branch
PTCA 5 percutaneous transluminal coronary
angioplasty
RCA 5 right coronary artery
Table 1. History, Risk Factors and Procedural Details of the
Study Group
Age (yrs) 66.7 6 7.2 (mean 6 SD)
Female gender 13/40 (32.5%)
Risk Factors
Tobacco smoking 22/40 (55%)
Hypercholesterolemia 11/40 (28%)
Arterial hypertension 25/40 (63%)
Diabetes mellitus 9/40 (23%)
Family history 6/40 (15%)
CAD Status at the Time of
Stenting
Target Vessel (n 5 44)
Asymptomatic 9 (22%) LAD 14 (32%)
Stable angina 18 (45%) CX and OM 14 (32%)
Unstable angina 13 (33%) RCA 14 (32%)
OM graft 2 (4%)
Stent Type (n 5 47) Stent Size (n 5 47)
Palmaz-Schatz 28 (59%) 3.0 37 (79%)
Gianturco-
Roubin II
4 (9%) 3.5 6 (13%)
Multilink 6 (13%) 4.0 3 (6%)
AVE 6 (13%) 4.5 1 (2%)
Crown 3 (6%)
CX 5 circumflex; LAD 5 left anterior descending; OM 5 obtuse marginal; RCA 5
right coronary artery.
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tion of either antiplatelet drug and experienced no adverse
event. One patient (F.D.), who was subjected to surgery two
days after stenting, experienced stent thrombosis with car-
diac arrest. He was successfully treated with an emergency
PTCA but required hospitalization for more than seven
weeks.
Five patients had no discontinuation of ticlopidine before
surgery. Three of these patients (G.W., R.C., W.A.)
underwent surgery less than three days from stenting, and
each expired. One (G.W.) required reoperation twice for
hematoma. Ticlopidine was then stopped. He died suddenly
four days later at home while experiencing severe chest pain
and was presumed to have an MI. Another patient (R.C.)
required reoperation for hemothorax and needed 11 units of
blood transfused. He died of deteriorating heart failure on
postoperative day 3. A third patient, (W.A.) required
reoperation 4 h after surgery for bleeding. Four hours later
he developed an acute inferior MI with recurrent ventricular
tachycardia and died seven days later. Two other patients
underwent surgery one day and five days after stenting,
respectively, and both made uneventful recoveries.
Of eight deceased patients, one had no discontinuation of
either antiplatelet drug, two patients had ticlopidine with-
drawn and aspirin continued, and six patients had both
drugs stopped 0 to 2 days before going to surgery (zero
denoting the day of surgery).
In the remaining 32 patients, most had both antiplatelet
drugs discontinued 0 to 1 day before and restarted 0 to 1 day
after surgery.
Patients who underwent surgery less than two weeks after
coronary stenting (n 5 25) were subjected to similar types of
surgical procedures as those undergoing surgery between
two and six weeks (n 5 15). The percent of patients
receiving abciximab during the stent placement was also
similar in both subgroups (5/25 vs. 4/15). The following
case histories provide insight into the dynamics of these
events.
CASE REPORTS
Case 1 (1996). A 67-year-old man with a history of CAD
treated with PTCA and COPD was evaluated before
resection of an infrarenal aortic aneurysm. A 90% restenosis
lesion in the midportion of the circumflex artery was
successfully treated with PTCA and a 3.0-mm Palmaz-
Schatz stent (Fig. 1, A and B). Ticlopidine was started the
day of PTCA and was stopped one day later. Aspirin,
continued from before the procedure, was stopped two days
after stenting, i.e., the day the patient underwent aneurys-
mectomy.
Six days after surgery, the patient became hypotensive.
His ECG at that time revealed 2 to 3 mm ST segment
depression in leads V3 to V6. An episode of ventricular
fibrillation followed the hypotension, and the patient was
successfully defibrillated. The patient underwent emergent
cardiac catheterization that revealed 100% occlusion of theTa
bl
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Figure 1. Patient F.D., case history #1. (A) 70% eccentric stenosis
of the circumflex coronary artery. (B) After successful placement of
3.0 Palmaz-Schatz coronary stent. (C) Total occlusion due to stent
thrombosis on the sixth day after surgery.
Figure 2. Patient J.C., case history #2. (A) Initial angiographic
appearance of the lesion in the circumflex coronary artery. (B)
Postprocedural result with 3.0 Palmaz-Schatz stent. (C) Total
thrombotic occlusion of the previously stented site on the first
postoperative day, not amenable to angioplasty.
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circumflex artery in the previously stented segment (Fig.
1C). The occluded artery was successfully opened by
PTCA. The ECG changes resolved after PTCA, and there
was no subsequent formation of Q waves. Creatine kinase
MB levels were not obtained. Ticlopidine was restarted and
continued for four weeks from stenting. The patient sur-
vived; however, his hospitalization was prolonged to over
seven weeks because of slow weaning from the mechanical
ventilator.
Case 2 (1997). A 62-year-old woman with interstitial
pulmonary fibrosis was evaluated for lung transplantation.
Cardiac catheterization revealed an 80% stenosis of the
proximal circumflex artery. The patient underwent PTCA
resulting in a nonocclusive dissection, which was success-
fully treated with a 3.0-mm Palmaz-Schatz stent (Fig. 2, A
and B). Ticlopidine was started on the day of the PTCA.
Aspirin, continued from before the procedure, was stopped
together with ticlopidine five days after stenting, i.e., the day
the patient underwent single lung transplant.
Twenty-four hours after transplantation, the patient de-
veloped respiratory distress, hypotension and 2 to 3 mm ST
segment elevation in ECG leads V3 to V6. Emergency
coronary angiography revealed 100% occlusion of the stent
(Fig. 2C). All attempts to cross this occlusion with a
guidewire were unsuccessful. An intraaortic balloon pump
was placed. New Q waves were subsequently noted on the
ECG. Ticlopidine and aspirin were restarted one day later.
On the sixth postoperative day, the patient suffered a
hemorrhagic cerebrovascular accident. She was declared
brain dead and expired on postoperative day 11. An autopsy
revealed a recent lateral wall MI. The stent site was patent.
Case 3 (1998). A 72-year-old woman with known CAD
was admitted for work-up of chronic iron deficiency anemia.
On cardiac catheterization, a 95% lesion in mid-LAD was
revealed and treated with a 3.5-mm Crown stent. Three
days later the colonoscopy disclosed an infiltrating, partially
obstructing sigmoid adenocarcinoma. Thus, she was sub-
jected to sigmoid colectomy five days after coronary stent-
ing. Ticlopidine and aspirin were discontinued on the day of
surgery. Two hours after surgery, she developed bradycardia
and severe ECG changes consistent with an acute anterior
MI (Fig. 3) and pulmonary edema requiring reintubation.
Two days later, in the intensive care unit, she extubated
herself, went into respiratory arrest and could not be
resuscitated.
DISCUSSION
This study reveals an extraordinarily high incidence of
catastrophic perioperative complications in patients who
undergo elective or semielective noncardiac surgery soon
after implantation of a coronary stent. These complications
include acute MI and death, which appear to be directly or
indirectly related to the preceding coronary intervention
because all the ischemic manifestations occurred in the
distribution of the stented arteries.
Through their use in interventional cardiology, intracoro-
nary stents have dramatically improved the outcome of
percutaneous coronary intervention by reducing the need for
emergent bypass surgery, improving immediate angio-
graphic results and reducing the rate of subsequent resten-
osis. Consequently, they are now used in more than 50% of
all PTCA procedures (7) and up to 90% in some hospitals.
Some of these procedures are performed for the purpose of
treating critical coronary lesions in patients who will subse-
quently undergo elective or semielective surgery. Treating
these lesions before surgery is expected to reduce the
incidence of perioperative and postoperative complications.
When first introduced, stents were plagued by a high rate
of acute or subacute thrombosis, which was generally
attended by acute MI (8). However, current technical
Figure 3. Patient V.G., case history #3. Electrocardiogram recorded during chest pain and symptoms of pulmonary edema. Bradycardia
and ST segment changes consistent with myocardial infarction.
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advances, such as high pressure balloon deployment (9) and
more effective antiplatelet regimens, have reduced the rate
of thrombosis to less than 1%. This low rate of thrombotic
closure is supported by recent clinical trial data (10–13).
The Fifth American College of Chest Physicians Con-
sensus on Antithrombotic Therapy has recently formulated
recommendations for antiplatelet therapy after coronary
stent placement. Patients who are at high risk for stent
thrombosis should be given ticlopidine for 30 days, and all
other patients should receive ticlopidine for at least 14 days
(14). It is also known that the use of aspirin without
ticlopidine results in a five times greater incidence of stent
thrombosis (12). Ticlopidine reaches peak antiplatelet effect
in approximately three to five days from initiation (15), and
patients who are treated with ticlopidine for several days
before stent placement have a significantly lower incidence
of procedural non-Q wave MI than those who begin
ticlopidine the day of the procedure (16).
In the group of patients reported herein, the most
catastrophic adverse event appeared to be stent thrombosis,
which usually leads to MI and death. In two patients, stent
thrombosis was documented angiographically. In five oth-
ers, stent thrombosis was presumed to be responsible since
the MI occurred in the territory supplied by the stented
artery. In this group of patients, one or both antiplatelet
drugs were typically interrupted one to two days before
surgery, which would be the general practice in patients
about to undergo surgery. The impact of abrupt withdrawal
or interruption from this antithrombotic regimen seems to
account for the unacceptable rate of acute coronary throm-
bosis.
Of note, all of the major adverse events occurred in
patients who underwent surgery within 14 days of stent
implantation. The interruption or withdrawal of the anti-
platelet regimen in this two-week window coincidentally
corresponds with the time frame during which stent throm-
bosis would likely occur and would appear to explain the
high incidence of stent thrombosis. Of the total seven MIs,
four occurred within 24 h of the surgical procedure, while
the other three developed at 6, 7 and 11 days after
procedure. Overall, 8 of the 25 patients who underwent
surgery within 14 days of stent placement expired within 11
days of the surgical procedure after suffering an MI or
significant bleeding episode.
Bleeding complications were unusually high and were
often combined with stent thrombosis. Aspirin (17) and
ticlopidine (18,19), used to prevent stent thrombosis, are
known to increase the risk of bleeding when administered
before a surgical procedure. Some of the patients had no
discontinuation of either medication after stent placement,
placing them at an even higher risk for bleeding. The
pharmacodynamics of both drugs make stopping either drug
1 to 2 days before surgery ineffective in diminishing the risk
of bleeding.
Thus, stent implantation before surgery appears to be a
double-edge sword. If antiplatelet drugs are withheld, the
likelihood of stent thrombosis is greatly enhanced. If anti-
platelet therapy is continued, the risk of postoperative
bleeding is increased. Since neither of these alternatives is
acceptable, elective surgery should be delayed for at least
two weeks after coronary stent implantation.
Some of the patients included in this study did undergo
noncardiac surgery early after stenting but did not have a
major cardiac complication. Five of these patients, however,
did experience excessive, but not catastrophic, bleeding
complications.
The relationship between performing elective noncardiac
surgery shortly after coronary stenting and the serious
adverse consequences of such action has been overlooked.
From the perspective of individual physicians, these disas-
trous events may have been perceived as single-case com-
plications. Yet, when data from a high volume angioplasty
and surgery center is revealed, the results are alarming.
In contrast to the alarming results of this study, when
PTCA was performed before, or in preparation for noncar-
diac surgery, earlier studies have demonstrated a reduction
of perioperative cardiac complications (3–6). While patients
who undergo PTCA without stent placement are benefited
by antiplatelet therapy, they are less prone to thrombosis
than patients who do have stents implanted since aspirin
alone is protective (14). The discontinuation of antiplatelet
therapy in the perioperative period does not appear to be
attended by the same thrombotic catastrophe that we
observed in stented patients. Hence, when a coronary
intervention is performed in a patient who is being consid-
ered for surgery soon after coronary intervention, efforts
should be made to avoid stent placement if possible.
This review provides guidelines for the care of a patient
who undergoes stent implantation and proceeds to elective
noncardiac surgery. Based on those observations, cardiolo-
gists and surgeons should refrain from performing noncar-
diac elective operations within 14 days of coronary stenting,
when interruption of the poststent antiplatelet treatment
appears to directly contribute to adverse and often fatal
events after surgery. In patients whose surgery is semielec-
tive or emergent, the decision to proceed with or to delay
surgery should be made with full weighing of the relative
risks inherent in either choice.
Study limitations. It may be argued that this study repre-
sents a retrospective observational analysis performed in a
cohort that is very heterogeneous in terms of the variety of
stents used, the different complexities of the interventional
and surgical procedures and the variety of operators. How-
ever, we believe that the uniformity of the outcome (unfa-
vorable) despite the heterogeneity of the cohort bespeaks a
strong message and obviates the need for a randomized trial.
Conclusions. We postulate that elective noncardiac sur-
gery should be postponed for several weeks after coronary
stenting, allowing the completion of currently recom-
mended 2 to 4 weeks of antiplatelet therapy. This would be
expected to keep the acute and subacute stent thrombosis
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rates equal to the general population of patients undergoing
coronary stenting. Additionally, for the limitation of peri-
operative bleeding, it would be ideal to wait several further
days for aspirin and ticlopidine to stop exerting their effects.
It should be also borne in mind that optimal “stent-like”
results can be obtained by conventional balloon PTCA with
ultrasound guidance (20,21) and may be a substitute for
elective coronary stenting. This alternative might be ideal
for CAD patients awaiting later noncardiac surgery because
such an approach would at least exclude the potential
hazards of aggressive two-drug antiplatelet therapy obliga-
tory after stenting. A recent study showed that optimal
balloon angioplasty with provisional stenting (used for
bail-out or early loss after 30 min only) is equivalent to
primary stenting in event-free survival, target vessel revas-
cularization and restenosis at six months (22). Although not
universally accepted for patients undergoing percutaneous
revascularization, such approaches are at least proven feasi-
ble and safe and, thus, may supersede stenting in the specific
cohort of CAD patients undergoing PTCA as a result of
cardiac work-up before elective noncardiac surgery.
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